How to Participate in Research: Steps 1, 2, 3

Please call 206-744-0588 or email us at uwadrc@uw.edu and leave us a message with your name and phone number.

A staff member will get back to you within 1-2 weeks to walk you through some pre-screening questions over the phone.

The pre-screening questions will help us identify studies that might be a good fit for you.

To learn more about current studies in the meantime, please explore the list of enrolling clinical trials and studies below on this webpage.

 

Check out the following online resources to learn more:

 

 

UW ADRC scientists want to learn more about the diseases that cause memory loss and dementia. Our center is looking for a variety of people who are willing to partner with us in Alzheimer's research. We think of study participants as our partners in the effort to find a prevention for neurological conditions that lead to dementia. New opportunities for observational studies or interventional clinical trials appear over time, and these may involve different groups of patients. The goals of these studies may be to:

►Help us understand more about how these diseases change the brain, through studying people with methods like neurologic examination, brain imaging, and cognitive tests.

►Help us understand what triggers these changes

►Test the safety and effectiveness of treatments that may prevent or delay these changes

 

Enrolling Clinical Studies and Trials

You may be eligible if you have:

AHEAD Study (BAN2401)

The AHEAD Study is testing whether an investigational treatment can lower people’s risk of memory loss due to Alzheimer’s disease.

Researchers have learned that changes in the brains of people with Alzheimer’s disease start as many as 20 years before they notice symptoms like memory problems. During those two decades, a protein in the brain called “amyloid” builds up in people who go on to have memory problems because of Alzheimer’s disease. While not all people with amyloid in their brain will develop memory problems, we know that the people who do are at a higher risk for developing the disease.

The study is funded by the National Institutes of Health, in partnership with the pharmaceutical company Eisai. It is being conducted by the NIH-funded Alzheimer’s Clinical Trial Consortium (ACTC), a network of leading academic Alzheimer’s research centers.

 

WHAT IS THE AHEAD STUDY?

The AHEAD Study is comprised of two different clinical trials testing the same investigational drug (known as BAN2401 (lecanemab)) in people who may be at risk for memory problems. Participants will receive personalized study treatment, instead of a one-size-fits-all approach. Study participants are enrolled in one of two AHEAD trials based on the level of amyloid in their brain: 

Participants with intermediate amyloid levels take part in the AHEAD A-3 trial—the first ever trial aimed at what may be the earliest signs of Alzheimer’s disease. Participants in the AHEAD A-3 trial will receive BAN2401 (lecanemab) once every 4 weeks for 4 years.

Participants with elevated amyloid levels take part in the AHEAD A-45 trial. Participants in the AHEAD A-45 trial will receive BAN2401 (lecanemab) once every 2 weeks for about 2 years and then once every 4 weeks for the remainder of the study.

Participants in both trials will receive intravenous (IV) infusions of BAN2401 (lecanemab), tailored to their risk of developing memory loss, or a placebo, an inactive substance designed to mimic the appearance of the drug. The infusion takes approximately 60 minutes.

At different points in the study, participants have a PET scan (or Positron Emission Tomography brain scan), to look at amyloid and tau (another protein) in their brain. This helps the participants and researchers track their health and this is the first study of its kind to use PET scans to measure amyloid and tau in all participants. The PET scan takes pictures of participants’ brains, allowing researchers to see and track changes in amyloid and tau levels.

 

ELIGIBILITY

Participants Eligible for the AHEAD Study:

Are healthy adults ages 55-80.

Have not been diagnosed with Alzheimer’s disease or another dementia.

Have a study partner, either a close relative or friend, who will participate in one study visit per year.

Have elevated or intermediate levels of amyloid in their brain, found by imaging as part of the study.

Learn More

 

PARTICIPATION REQUIREMENTS

Learn about what you will do as a study participant

 

UW ADRC Site Contact:

Kinsey Chapman

kinseyc@uw.edu

206-744-0446

 

UW ADRC Site PI:

Darla Chapman, Clinical Trials Coordinator and Clinician, ADRC

For More Information

Late Onset Alzheimer’s Disease Study NIA- LOAD

We are studying families with histories of dementia to understand the genetic components behind Alzheimer’s disease. 

 

You may qualify for this study if you meet these requirements: 

-Have living family member(s) with a diagnosis of Alzheimer’s disease or related dementia

-Have a friend, family member, or caretaker who is able and willing to answer questions about you 

-Are willing to be contacted every  1-2 years to complete memory testing and an interview, both of which can be completed over the phone

 

Contact

For more information, please contact the Research Coordinator at 206.277.1024

 

Study Leader

Debby Tsuang, MD, Professor, Psychiatry & Behavioral Sciences/ Adjunct Professor, Epidemiology
Director, GRECC, VISN-20 Geriatric Research, Education, and Clinical Center
Psychiatrist, Clinical Core,  ADRC

For More Information

Novo Nordisk Evoke +

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

If you or someone you love is increasingly becoming forgetful, experiencing difficulties in planning and problem solving, or getting lost in familiar places, these could be signs of early Alzheimer’s disease. 

Contact us today to find out more about the evoke+ clinical study. 

Consider participating in the study if: 

You (may) have early Alzheimer’s disease. 

You are between 55 and 85 years old. 

You have a study partner (a next of kin or someone you have a close relationship with), who is willing to take part in the study and share information about you. 

The study doctor will explain any potential risks to you and describe the study procedures before you decide whether to join the study. 

If eligible, you will be one of over 3500 participants worldwide on this 3-year journey and will receive regular clinic visits, health checkups, and medical testing. You will get access to expert guidance and facilities during the study. 

 

UW ADRC Contact:

Kristin Farris, UW Study Coordinator

Phone 206-897-6797

Email kmfarris@uw.edu


RethinkAlz (simufilam)

RethinkALZ is a a new clinical trial for Alzheimer's Disease. The purpose of this trial is to determine if a new, twice-a-day, oral drug candidate called simufilam is safe and effective in slowing down the progression of mild-to-moderate Alzheimer’s disease. Simufilam is an investigational drug candidate that has not been approved by the US Food and Drug Administration (FDA), or any regulatory agency, for the treatment of any condition.

Simufilam (formerly known as PTI-125) is an investigational drug that represents an entirely new approach to treat Alzheimer’s disease.

Importantly, we do not seek to clear amyloid out of the brain. Our science is based on stabilizing a critical protein in the brain.

Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. (For a video and description of the drug, please visit: https://www.cassavasciences.com/simufilam)

 

Participants who are eligible for the RethinkALZ study must:

  • Be ages 50 to 87 years old
  • Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease
  • Have a gradual change in memory for six months or more
  • Have a family member or loved one who can be available as a study partner during the entire study
  • Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection  

Other criteria will apply.

The RethinkALZ study is now open to qualifying participants. The trial lasts 52 weeks. If you enroll into this trial, you will receive either the oral study drug or placebo twice a day. A placebo looks like the study drug but has no impact on the person taking it. There is no cost to the patient to participate in the RethinkALZ trial or for any of the study-related procedures. No hospitalization is required. You may be compensated for your time and travel for each clinical study appointment.

To learn more about the RethinkALZ study, please contact our local UW study coordinator: 

 

Megan Zdancewic

Email: meganz2@uw.edu

Phone: 206-823-4847

 

UW ADRC Site PI:

Charles Bernick, MD, MPH, Director of Clinical Trials, MBWC


Technology for Early Dementia Diagnosis

Researchers at the VA Geriatric Research, Education, and Clinical Centers are studying wearable technologies that may be useful to help diagnose Alzheimer's disease and dementia with Lewy bodies.

ELIGIBILITY

You may qualify for this study if you meet these requirements:

-Have a diagnosis of Alzheimer's disease or probable dementia with Lewy Bodies

-Have a friend, family member, or caretaker who is able and willing to answer questions about you

-Have at least 8 years of education

 

COMPENSATION

Volunteers who complete this study will receive up to $250 in appreciation for their time and participation.

 

CONTACT

Study Contact: Sarah Payne | 206.277.1379

Study PI: Debby Tsuang, MD, Professor, UW Psychiatry & Behavioral Sciences/ Leader of the Dementia with Lewy Body Consortium Study site at the VA Puget Sound Health Care Center/UW


Late Onset Alzheimer’s Disease Study NIA- LOAD

We are studying families with histories of dementia to understand the genetic components behind Alzheimer’s disease. 

 

You may qualify for this study if you meet these requirements: 

-Have living family member(s) with a diagnosis of Alzheimer’s disease or related dementia

-Have a friend, family member, or caretaker who is able and willing to answer questions about you 

-Are willing to be contacted every  1-2 years to complete memory testing and an interview, both of which can be completed over the phone

 

Contact

For more information, please contact the Research Coordinator at 206.277.1024

 

Study Leader

Debby Tsuang, MD, Professor, Psychiatry & Behavioral Sciences/ Adjunct Professor, Epidemiology
Director, GRECC, VISN-20 Geriatric Research, Education, and Clinical Center
Psychiatrist, Clinical Core,  ADRC

For More Information

RethinkAlz (simufilam)

RethinkALZ is a a new clinical trial for Alzheimer's Disease. The purpose of this trial is to determine if a new, twice-a-day, oral drug candidate called simufilam is safe and effective in slowing down the progression of mild-to-moderate Alzheimer’s disease. Simufilam is an investigational drug candidate that has not been approved by the US Food and Drug Administration (FDA), or any regulatory agency, for the treatment of any condition.

Simufilam (formerly known as PTI-125) is an investigational drug that represents an entirely new approach to treat Alzheimer’s disease.

Importantly, we do not seek to clear amyloid out of the brain. Our science is based on stabilizing a critical protein in the brain.

Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. (For a video and description of the drug, please visit: https://www.cassavasciences.com/simufilam)

 

Participants who are eligible for the RethinkALZ study must:

  • Be ages 50 to 87 years old
  • Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease
  • Have a gradual change in memory for six months or more
  • Have a family member or loved one who can be available as a study partner during the entire study
  • Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection  

Other criteria will apply.

The RethinkALZ study is now open to qualifying participants. The trial lasts 52 weeks. If you enroll into this trial, you will receive either the oral study drug or placebo twice a day. A placebo looks like the study drug but has no impact on the person taking it. There is no cost to the patient to participate in the RethinkALZ trial or for any of the study-related procedures. No hospitalization is required. You may be compensated for your time and travel for each clinical study appointment.

To learn more about the RethinkALZ study, please contact our local UW study coordinator: 

 

Megan Zdancewic

Email: meganz2@uw.edu

Phone: 206-823-4847

 

UW ADRC Site PI:

Charles Bernick, MD, MPH, Director of Clinical Trials, MBWC


Technology for Early Dementia Diagnosis

Researchers at the VA Geriatric Research, Education, and Clinical Centers are studying wearable technologies that may be useful to help diagnose Alzheimer's disease and dementia with Lewy bodies.

ELIGIBILITY

You may qualify for this study if you meet these requirements:

-Have a diagnosis of Alzheimer's disease or probable dementia with Lewy Bodies

-Have a friend, family member, or caretaker who is able and willing to answer questions about you

-Have at least 8 years of education

 

COMPENSATION

Volunteers who complete this study will receive up to $250 in appreciation for their time and participation.

 

CONTACT

Study Contact: Sarah Payne | 206.277.1379

Study PI: Debby Tsuang, MD, Professor, UW Psychiatry & Behavioral Sciences/ Leader of the Dementia with Lewy Body Consortium Study site at the VA Puget Sound Health Care Center/UW


ADRC Clinical Core

Who we are

The UW Alzheimer’s Disease Research Center (ADRC) is part of a nationwide network of research centers funded by the National Institute on Aging to learn more about Alzheimer’s disease and related dementias.  We are exploring innovative approaches to diagnosis, treatment, and disease prevention by partnering with people who have normal memory and thinking and those who have memory concerns or are living with dementia.  

In order to learn more about diseases that cause memory loss and dementia, we are looking for volunteers from a variety of ethnic backgrounds and ages who are willing to participate in research.  It is important to study a diverse group of people so that the information we learn will benefit everyone.

 

Who we are seeking

The UW ADRC is interested in partnering with:

-People from underrepresented groups, such as African Americans, Hispanics, American Indians and Alaskan Natives.  

-People diagnosed with memory and thinking (cognitive) changes by their medical provider, especially a diagnosis of Mild Cognitive Impairment

-We are also interested in partnering with people from any ethnic background who are 85 years or older and who do not have concerns about their memory or thinking. 

 

What to expect at a UW ADRC research visit

This study involves a yearly visit during which volunteers complete tests of their memory and thinking, have a brief physical and neurological examination, and answer questions about their medical history, memory, mood, and ability to perform daily activities. Volunteers must also have a study partner who knows them well and would notice changes in their memory, mood or ability to perform daily activities.  

We may also ask some volunteers for a blood or cerebral spinal fluid sample in order to learn more about how our bodies change in response to normal aging and dementia.

To learn more about participating, contact: UW ADRC at 206-744-0588,  uwadrc@uw.edu

For More Information

Late Onset Alzheimer’s Disease Study NIA- LOAD

We are studying families with histories of dementia to understand the genetic components behind Alzheimer’s disease. 

 

You may qualify for this study if you meet these requirements: 

-Have living family member(s) with a diagnosis of Alzheimer’s disease or related dementia

-Have a friend, family member, or caretaker who is able and willing to answer questions about you 

-Are willing to be contacted every  1-2 years to complete memory testing and an interview, both of which can be completed over the phone

 

Contact

For more information, please contact the Research Coordinator at 206.277.1024

 

Study Leader

Debby Tsuang, MD, Professor, Psychiatry & Behavioral Sciences/ Adjunct Professor, Epidemiology
Director, GRECC, VISN-20 Geriatric Research, Education, and Clinical Center
Psychiatrist, Clinical Core,  ADRC

For More Information

MAP: Metformin in Alzheimer’s Dementia Prevention

 JOIN US IN OUR FIGHT TO HELP PREVENT DEMENTIA 

MAP: Metformin in Alzheimer's Dementia Prevention is a research study looking at an existing drug used for diabetes prevention. The study tests if this drug can help prevent a decline in memory and thinking abilities for people with mild memory problems. It is a randomized study in which you will take either metformin (Glucophage® XR) or a placebo. 

Randomized means you will have an equal opportunity of getting the study drug or placebo. A placebo is a pill that looks the same as the study drug, but has no medicine. 

There will be no charge to you for the study drug or study visits. 

Taking part in this study is completely voluntary. We appreciate your participation. 

MAP is a multi-center study, where people can take part in the study at 11 locations throughout the United States. It is funded by the National Institutes of Health (NIH) through the National Institute on Aging (NIA). Our researchers are experienced in running research studies. They are also experts in the field of memory loss, dementia, and Alzheimer’s disease. We invite you to join us in our search for treatments to improve the lives of those with memory problems due to Alzheimer’s disease. 

 

 You may be able to join if: 

  • you are 55-90 years old, 
  • you or your loved ones have noticed some changes in your memory, and 
  • you are not already being treated for diabetes or dementia 

 

Potential benefits:

  • You will receive some of your blood test results. We can also share these results with your healthcare provider.
  • Your participation may improve the prevention of dementia for future generations.

 

Taking part in MAP is voluntary and will not affect the care you receive.  If you decide to join, you will be compensated for your time. You may earn up to $850 for completing all study-related visits. 

 

To learn more about the MAP study, please contact our local UW study coordinator: 

Hanson Research Team 

(206) 744-1851 or (206) 897-5393

hansonlab@uw.edu 

 

Visit us at: https://www.iths.org/participate/metformin-in-alzheimers-dementia-prevention-map/


Novo Nordisk Evoke +

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

If you or someone you love is increasingly becoming forgetful, experiencing difficulties in planning and problem solving, or getting lost in familiar places, these could be signs of early Alzheimer’s disease. 

Contact us today to find out more about the evoke+ clinical study. 

Consider participating in the study if: 

You (may) have early Alzheimer’s disease. 

You are between 55 and 85 years old. 

You have a study partner (a next of kin or someone you have a close relationship with), who is willing to take part in the study and share information about you. 

The study doctor will explain any potential risks to you and describe the study procedures before you decide whether to join the study. 

If eligible, you will be one of over 3500 participants worldwide on this 3-year journey and will receive regular clinic visits, health checkups, and medical testing. You will get access to expert guidance and facilities during the study. 

 

UW ADRC Contact:

Kristin Farris, UW Study Coordinator

Phone 206-897-6797

Email kmfarris@uw.edu


The Remote Cog Study

Researchers at the VA Puget Sound Hospital in Seattle are seeking volunteers for the Remote Cog Study. Black Americans often miss out on early care that can help with memory and mental health changes. We hope to learn how to spot these changes earlier in Black Americans.

We are enrolling Black Americans who are age 65+, concerned about their memory, and interested in a 10-week research study from the comfort of their own homes that includes: 

 

Answering health-related questions using paper, a telephone, and a mobile device 

Using several devices at home, including a wristwatch, thermometer, and blood pressure monitor 

Providing a blood sample 

 

Learn more

Please contact us at (206) 277-1379 for more information.

The lead researcher of this study is Dr. Debby Tsuang at S182 GRECC, VA Puget Sound, 1660 S. Columbian Way, Seattle WA 98108.

For More Information

ADRC Clinical Core

Who we are

The UW Alzheimer’s Disease Research Center (ADRC) is part of a nationwide network of research centers funded by the National Institute on Aging to learn more about Alzheimer’s disease and related dementias.  We are exploring innovative approaches to diagnosis, treatment, and disease prevention by partnering with people who have normal memory and thinking and those who have memory concerns or are living with dementia.  

In order to learn more about diseases that cause memory loss and dementia, we are looking for volunteers from a variety of ethnic backgrounds and ages who are willing to participate in research.  It is important to study a diverse group of people so that the information we learn will benefit everyone.

 

Who we are seeking

The UW ADRC is interested in partnering with:

-People from underrepresented groups, such as African Americans, Hispanics, American Indians and Alaskan Natives.  

-People diagnosed with memory and thinking (cognitive) changes by their medical provider, especially a diagnosis of Mild Cognitive Impairment

-We are also interested in partnering with people from any ethnic background who are 85 years or older and who do not have concerns about their memory or thinking. 

 

What to expect at a UW ADRC research visit

This study involves a yearly visit during which volunteers complete tests of their memory and thinking, have a brief physical and neurological examination, and answer questions about their medical history, memory, mood, and ability to perform daily activities. Volunteers must also have a study partner who knows them well and would notice changes in their memory, mood or ability to perform daily activities.  

We may also ask some volunteers for a blood or cerebral spinal fluid sample in order to learn more about how our bodies change in response to normal aging and dementia.

To learn more about participating, contact: UW ADRC at 206-744-0588,  uwadrc@uw.edu

For More Information

AHEAD Study (BAN2401)

The AHEAD Study is testing whether an investigational treatment can lower people’s risk of memory loss due to Alzheimer’s disease.

Researchers have learned that changes in the brains of people with Alzheimer’s disease start as many as 20 years before they notice symptoms like memory problems. During those two decades, a protein in the brain called “amyloid” builds up in people who go on to have memory problems because of Alzheimer’s disease. While not all people with amyloid in their brain will develop memory problems, we know that the people who do are at a higher risk for developing the disease.

The study is funded by the National Institutes of Health, in partnership with the pharmaceutical company Eisai. It is being conducted by the NIH-funded Alzheimer’s Clinical Trial Consortium (ACTC), a network of leading academic Alzheimer’s research centers.

 

WHAT IS THE AHEAD STUDY?

The AHEAD Study is comprised of two different clinical trials testing the same investigational drug (known as BAN2401 (lecanemab)) in people who may be at risk for memory problems. Participants will receive personalized study treatment, instead of a one-size-fits-all approach. Study participants are enrolled in one of two AHEAD trials based on the level of amyloid in their brain: 

Participants with intermediate amyloid levels take part in the AHEAD A-3 trial—the first ever trial aimed at what may be the earliest signs of Alzheimer’s disease. Participants in the AHEAD A-3 trial will receive BAN2401 (lecanemab) once every 4 weeks for 4 years.

Participants with elevated amyloid levels take part in the AHEAD A-45 trial. Participants in the AHEAD A-45 trial will receive BAN2401 (lecanemab) once every 2 weeks for about 2 years and then once every 4 weeks for the remainder of the study.

Participants in both trials will receive intravenous (IV) infusions of BAN2401 (lecanemab), tailored to their risk of developing memory loss, or a placebo, an inactive substance designed to mimic the appearance of the drug. The infusion takes approximately 60 minutes.

At different points in the study, participants have a PET scan (or Positron Emission Tomography brain scan), to look at amyloid and tau (another protein) in their brain. This helps the participants and researchers track their health and this is the first study of its kind to use PET scans to measure amyloid and tau in all participants. The PET scan takes pictures of participants’ brains, allowing researchers to see and track changes in amyloid and tau levels.

 

ELIGIBILITY

Participants Eligible for the AHEAD Study:

Are healthy adults ages 55-80.

Have not been diagnosed with Alzheimer’s disease or another dementia.

Have a study partner, either a close relative or friend, who will participate in one study visit per year.

Have elevated or intermediate levels of amyloid in their brain, found by imaging as part of the study.

Learn More

 

PARTICIPATION REQUIREMENTS

Learn about what you will do as a study participant

 

UW ADRC Site Contact:

Kinsey Chapman

kinseyc@uw.edu

206-744-0446

 

UW ADRC Site PI:

Darla Chapman, Clinical Trials Coordinator and Clinician, ADRC

For More Information

Late Onset Alzheimer’s Disease Study NIA- LOAD

We are studying families with histories of dementia to understand the genetic components behind Alzheimer’s disease. 

 

You may qualify for this study if you meet these requirements: 

-Have living family member(s) with a diagnosis of Alzheimer’s disease or related dementia

-Have a friend, family member, or caretaker who is able and willing to answer questions about you 

-Are willing to be contacted every  1-2 years to complete memory testing and an interview, both of which can be completed over the phone

 

Contact

For more information, please contact the Research Coordinator at 206.277.1024

 

Study Leader

Debby Tsuang, MD, Professor, Psychiatry & Behavioral Sciences/ Adjunct Professor, Epidemiology
Director, GRECC, VISN-20 Geriatric Research, Education, and Clinical Center
Psychiatrist, Clinical Core,  ADRC

For More Information

Latino Caregiver Research Study

Latino Caregiver Research Study (Spanish/English translations below)

 

Investigadores de la Universidad de Washington están desarrollando un programa para apoyar a cuidadores de familiares con enfermedad de Alzheimer o demencias relacionadas. Están interesados en hablar con familiares o amigos cercanos que son cuidadores de personas con demencia que tengan problemas de comportamiento como depresión, discusiones o rehusarse a bañarse y vestirse. 

Su participación es voluntaria y confidencial.

 

Buscamos personas que cumplan los siguientes requisitos:

-Se identifique como Hispano/Latino

-Cuiden a un familiar o amigo cercano con diagnóstico de enfermedad de Alzheimer u otra demencia r-elacionada

-Su familiar tiene problemas de comportamiento

 

Para participar necesita:

-Completar una encuesta (10 minutos) y participar en una entrevista por teléfono o Zoom.

-Recibirá una compensación de $45 en agradecimiento a su tiempo

 

Para participar en el estudio o recibir más información, favor de comunicarse con la Miriana Duran: mdp19@uw.edu ó 206-221-6206

 

______

Researchers at the University of Washington are developing a program to support family (or close friend) caregivers of individuals with Alzheimer’s disease or related dementia. They are interested in speaking with family caregivers that are caring for individuals experiencing behavior issues such as trying to leave the house, arguing, or refusing to bathe or get dressed.

Research is always voluntary.

 

This study might be a good fit for you if you:

-Identify as Hispanic/Latino

-Take care of a family member or close friend diagnosed with Alzheimer’s disease or other dementia

- Have a family member or close friend who is experiencing behavior issues

 

If you decide to take part in the research study:

-You will need to complete a 10 minute survey and a 1 hour interview by phone or Zoom.

-You will receive $45 to thank you for your time and effort

 

To learn more about the study, please contact Miriana Duran: mdp19@uw.edu or 206-221-6206


Lipid MRI Study

Dr. Angela Hanson, MD at the University of Washington is enrolling people for a NIH funded study to test how two simple nutrients, sugar and fat, can affect your memory, brain (via MRI Scan) and blood biomarkers. The Lipid MRI study involves non-invasive MRI imaging to see how a risk gene for Alzheimer’s disease, APOE4, affects brain blood flow after a high fat drink. With this study, we hope to understand what parts of the brain are most affected by a high fat meal.

 

YOU MAY BE ELIGIBLE IF

• You are age 55 or older

• You do not have Alzheimer's disease or dementia already

• You are not currently taking medication for diabetes

 

PARTICIPANTS WILL RECEIVE

• Information about dementia prevention

• Participants will be compensated for their time.

 

ABOUT

-The study involves one initial screening visit and one study visit. For both visits, we ask participants to fast in the morning (water and medications are still okay to take). Study participants will be compensated for their time.

-The screening visit takes place at the University of Washington South Lake Union campus and involves obtaining in-person consent, vitals, blood draws through an IV, a brief memory test, an oral glucose tolerance test, and a DEXA scan to measure body composition. The visit will last about 3.5 hours.

-The final study visit takes place at the University of Washington main campus. This visit involves blood draws through an IV, drinking dairy cream, two MRI scans, and cognitive testing on an iPad. The visit will last about 5 hours.

 

Contact: Hanson Research Team

Email: hansonlab@uw.edu

Phone: 206-897-5393


Meal and Memory Study

APOE genotype and diet influences on Alzheimer's biomarkers

We are learning more and more about the risks for Alzheimer's disease every year, and that includes learning what foods are best at promoting brain health. It might be more complicated than 'this food is good or bad.' Dr. Angela Hanson, a geriatric physician at the University of Washington, is conducting a study that examines how a risk gene for Alzheimer's disease might affect people's memory and metabolic responses to different meals. Her preliminary work showed that people who carry the gene APOE4 (E4) responded differently to different Alzheimer's treatments and diets, compared to people who did not carry this gene. Dr. Hanson plans to study this further with the "Meal and Memory Study” in adults age 55 and older who do not have dementia. 

 

Eligibility: Participants may be men or women, ages 55 and older. People who have known dementia, or known diabetes, are not eligible.

 

Key researcher:  Angela Hanson, MD

Study Contact: Angela Hanson at 206-897-5393 or hansonaj@uw.edu

For More Information

PoND: Prazosin and CSF Biomarkers in Aging, MCI and AD

We are seeking healthy, medically stable volunteers over the age of 45 who do not have memory problems for a new approach to preventing Alzheimer’s and other dementias.

Details

  • The study includes an assessment of your physical and mental health.
  • You will receive prazosin (a pill used for posttraumatic stress disorder and high blood pressure).
  • The study will take about 14 hours, spread over roughly 9 visits during a 3-month period.
  • These visits will be at the Seattle VA.
  • You will be compensated for each of your visits, with the total compensation for the study amounting to $750 to $825.

Key Researcher: The PI of this study is Murray Raskind at S-116-MIRECC, 1660 S. Columbian Way, Seattle, WA  98108.

Study Contact: 206.277.1491 or 1.800.329.8387 ext. 1491 

For More Information

The Remote Cog Study

Researchers at the VA Puget Sound Hospital in Seattle are seeking volunteers for the Remote Cog Study. Black Americans often miss out on early care that can help with memory and mental health changes. We hope to learn how to spot these changes earlier in Black Americans.

We are enrolling Black Americans who are age 65+, concerned about their memory, and interested in a 10-week research study from the comfort of their own homes that includes: 

 

Answering health-related questions using paper, a telephone, and a mobile device 

Using several devices at home, including a wristwatch, thermometer, and blood pressure monitor 

Providing a blood sample 

 

Learn more

Please contact us at (206) 277-1379 for more information.

The lead researcher of this study is Dr. Debby Tsuang at S182 GRECC, VA Puget Sound, 1660 S. Columbian Way, Seattle WA 98108.

For More Information

ADRC Clinical Core

Who we are

The UW Alzheimer’s Disease Research Center (ADRC) is part of a nationwide network of research centers funded by the National Institute on Aging to learn more about Alzheimer’s disease and related dementias.  We are exploring innovative approaches to diagnosis, treatment, and disease prevention by partnering with people who have normal memory and thinking and those who have memory concerns or are living with dementia.  

In order to learn more about diseases that cause memory loss and dementia, we are looking for volunteers from a variety of ethnic backgrounds and ages who are willing to participate in research.  It is important to study a diverse group of people so that the information we learn will benefit everyone.

 

Who we are seeking

The UW ADRC is interested in partnering with:

-People from underrepresented groups, such as African Americans, Hispanics, American Indians and Alaskan Natives.  

-People diagnosed with memory and thinking (cognitive) changes by their medical provider, especially a diagnosis of Mild Cognitive Impairment

-We are also interested in partnering with people from any ethnic background who are 85 years or older and who do not have concerns about their memory or thinking. 

 

What to expect at a UW ADRC research visit

This study involves a yearly visit during which volunteers complete tests of their memory and thinking, have a brief physical and neurological examination, and answer questions about their medical history, memory, mood, and ability to perform daily activities. Volunteers must also have a study partner who knows them well and would notice changes in their memory, mood or ability to perform daily activities.  

We may also ask some volunteers for a blood or cerebral spinal fluid sample in order to learn more about how our bodies change in response to normal aging and dementia.

To learn more about participating, contact: UW ADRC at 206-744-0588,  uwadrc@uw.edu

For More Information

Late Onset Alzheimer’s Disease Study NIA- LOAD

We are studying families with histories of dementia to understand the genetic components behind Alzheimer’s disease. 

 

You may qualify for this study if you meet these requirements: 

-Have living family member(s) with a diagnosis of Alzheimer’s disease or related dementia

-Have a friend, family member, or caretaker who is able and willing to answer questions about you 

-Are willing to be contacted every  1-2 years to complete memory testing and an interview, both of which can be completed over the phone

 

Contact

For more information, please contact the Research Coordinator at 206.277.1024

 

Study Leader

Debby Tsuang, MD, Professor, Psychiatry & Behavioral Sciences/ Adjunct Professor, Epidemiology
Director, GRECC, VISN-20 Geriatric Research, Education, and Clinical Center
Psychiatrist, Clinical Core,  ADRC

For More Information

Late Onset Alzheimer’s Disease Study NIA- LOAD

We are studying families with histories of dementia to understand the genetic components behind Alzheimer’s disease. 

 

You may qualify for this study if you meet these requirements: 

-Have living family member(s) with a diagnosis of Alzheimer’s disease or related dementia

-Have a friend, family member, or caretaker who is able and willing to answer questions about you 

-Are willing to be contacted every  1-2 years to complete memory testing and an interview, both of which can be completed over the phone

 

Contact

For more information, please contact the Research Coordinator at 206.277.1024

 

Study Leader

Debby Tsuang, MD, Professor, Psychiatry & Behavioral Sciences/ Adjunct Professor, Epidemiology
Director, GRECC, VISN-20 Geriatric Research, Education, and Clinical Center
Psychiatrist, Clinical Core,  ADRC

For More Information

Late Onset Alzheimer’s Disease Study NIA- LOAD

We are studying families with histories of dementia to understand the genetic components behind Alzheimer’s disease. 

 

You may qualify for this study if you meet these requirements: 

-Have living family member(s) with a diagnosis of Alzheimer’s disease or related dementia

-Have a friend, family member, or caretaker who is able and willing to answer questions about you 

-Are willing to be contacted every  1-2 years to complete memory testing and an interview, both of which can be completed over the phone

 

Contact

For more information, please contact the Research Coordinator at 206.277.1024

 

Study Leader

Debby Tsuang, MD, Professor, Psychiatry & Behavioral Sciences/ Adjunct Professor, Epidemiology
Director, GRECC, VISN-20 Geriatric Research, Education, and Clinical Center
Psychiatrist, Clinical Core,  ADRC

For More Information

Technology for Early Dementia Diagnosis

Researchers at the VA Geriatric Research, Education, and Clinical Centers are studying wearable technologies that may be useful to help diagnose Alzheimer's disease and dementia with Lewy bodies.

ELIGIBILITY

You may qualify for this study if you meet these requirements:

-Have a diagnosis of Alzheimer's disease or probable dementia with Lewy Bodies

-Have a friend, family member, or caretaker who is able and willing to answer questions about you

-Have at least 8 years of education

 

COMPENSATION

Volunteers who complete this study will receive up to $250 in appreciation for their time and participation.

 

CONTACT

Study Contact: Sarah Payne | 206.277.1379

Study PI: Debby Tsuang, MD, Professor, UW Psychiatry & Behavioral Sciences/ Leader of the Dementia with Lewy Body Consortium Study site at the VA Puget Sound Health Care Center/UW


The Dementia with Lewy Bodies Consortium Study

The Dementia with Lewy Bodies Consortium Study

The purpose of the Dementia with Lewy Bodies Consortium is to develop a collection of samples from individuals diagnosed with dementia with lewy bodies (DLB), dementia with lewy bodies/mild cognitive impairment (MCI), or Parkinson's disease dementia who will be followed over time. The consortium will collect detailed clinical information, biospecimens, and imaging data. Led by top leaders in the field, this consortium will fill the gap in resources available for biomarker development in Lewy Body Dementia and promote additional future research by having a readily available subject sample. 

 

You may qualify for this study if you:

-Have a diagnosis of probable dementia with lewy body/MCI or Parkinson's disease dementia

-Have a study partner who is able and willing to comply with required study procedures

-Have at least eight years of education

The study doctor will also check for other medical conditions or reasons that might prevent you from participating in the study

 

Study Leader: Debby Tsuang, MD, Professor, UW Psychiatry & Behavioral Sciences/ Leader of the Dementia with Lewy Body Consortium Study site at the VA Puget Sound Health Care Center/UW

Seattle Study Contact: Sarah Payne | 206.277.1379

For More Information

The Dementia with Lewy Bodies Consortium Study

The Dementia with Lewy Bodies Consortium Study

The purpose of the Dementia with Lewy Bodies Consortium is to develop a collection of samples from individuals diagnosed with dementia with lewy bodies (DLB), dementia with lewy bodies/mild cognitive impairment (MCI), or Parkinson's disease dementia who will be followed over time. The consortium will collect detailed clinical information, biospecimens, and imaging data. Led by top leaders in the field, this consortium will fill the gap in resources available for biomarker development in Lewy Body Dementia and promote additional future research by having a readily available subject sample. 

 

You may qualify for this study if you:

-Have a diagnosis of probable dementia with lewy body/MCI or Parkinson's disease dementia

-Have a study partner who is able and willing to comply with required study procedures

-Have at least eight years of education

The study doctor will also check for other medical conditions or reasons that might prevent you from participating in the study

 

Study Leader: Debby Tsuang, MD, Professor, UW Psychiatry & Behavioral Sciences/ Leader of the Dementia with Lewy Body Consortium Study site at the VA Puget Sound Health Care Center/UW

Seattle Study Contact: Sarah Payne | 206.277.1379

For More Information

Latino Caregiver Research Study

Latino Caregiver Research Study (Spanish/English translations below)

 

Investigadores de la Universidad de Washington están desarrollando un programa para apoyar a cuidadores de familiares con enfermedad de Alzheimer o demencias relacionadas. Están interesados en hablar con familiares o amigos cercanos que son cuidadores de personas con demencia que tengan problemas de comportamiento como depresión, discusiones o rehusarse a bañarse y vestirse. 

Su participación es voluntaria y confidencial.

 

Buscamos personas que cumplan los siguientes requisitos:

-Se identifique como Hispano/Latino

-Cuiden a un familiar o amigo cercano con diagnóstico de enfermedad de Alzheimer u otra demencia r-elacionada

-Su familiar tiene problemas de comportamiento

 

Para participar necesita:

-Completar una encuesta (10 minutos) y participar en una entrevista por teléfono o Zoom.

-Recibirá una compensación de $45 en agradecimiento a su tiempo

 

Para participar en el estudio o recibir más información, favor de comunicarse con la Miriana Duran: mdp19@uw.edu ó 206-221-6206

 

______

Researchers at the University of Washington are developing a program to support family (or close friend) caregivers of individuals with Alzheimer’s disease or related dementia. They are interested in speaking with family caregivers that are caring for individuals experiencing behavior issues such as trying to leave the house, arguing, or refusing to bathe or get dressed.

Research is always voluntary.

 

This study might be a good fit for you if you:

-Identify as Hispanic/Latino

-Take care of a family member or close friend diagnosed with Alzheimer’s disease or other dementia

- Have a family member or close friend who is experiencing behavior issues

 

If you decide to take part in the research study:

-You will need to complete a 10 minute survey and a 1 hour interview by phone or Zoom.

-You will receive $45 to thank you for your time and effort

 

To learn more about the study, please contact Miriana Duran: mdp19@uw.edu or 206-221-6206


Sort by Study Type

Latino Caregiver Research Study

Latino Caregiver Research Study (Spanish/English translations below)

 

Investigadores de la Universidad de Washington están desarrollando un programa para apoyar a cuidadores de familiares con enfermedad de Alzheimer o demencias relacionadas. Están interesados en hablar con familiares o amigos cercanos que son cuidadores de personas con demencia que tengan problemas de comportamiento como depresión, discusiones o rehusarse a bañarse y vestirse. 

Su participación es voluntaria y confidencial.

 

Buscamos personas que cumplan los siguientes requisitos:

-Se identifique como Hispano/Latino

-Cuiden a un familiar o amigo cercano con diagnóstico de enfermedad de Alzheimer u otra demencia r-elacionada

-Su familiar tiene problemas de comportamiento

 

Para participar necesita:

-Completar una encuesta (10 minutos) y participar en una entrevista por teléfono o Zoom.

-Recibirá una compensación de $45 en agradecimiento a su tiempo

 

Para participar en el estudio o recibir más información, favor de comunicarse con la Miriana Duran: mdp19@uw.edu ó 206-221-6206

 

______

Researchers at the University of Washington are developing a program to support family (or close friend) caregivers of individuals with Alzheimer’s disease or related dementia. They are interested in speaking with family caregivers that are caring for individuals experiencing behavior issues such as trying to leave the house, arguing, or refusing to bathe or get dressed.

Research is always voluntary.

 

This study might be a good fit for you if you:

-Identify as Hispanic/Latino

-Take care of a family member or close friend diagnosed with Alzheimer’s disease or other dementia

- Have a family member or close friend who is experiencing behavior issues

 

If you decide to take part in the research study:

-You will need to complete a 10 minute survey and a 1 hour interview by phone or Zoom.

-You will receive $45 to thank you for your time and effort

 

To learn more about the study, please contact Miriana Duran: mdp19@uw.edu or 206-221-6206


Technology for Early Dementia Diagnosis

Researchers at the VA Geriatric Research, Education, and Clinical Centers are studying wearable technologies that may be useful to help diagnose Alzheimer's disease and dementia with Lewy bodies.

ELIGIBILITY

You may qualify for this study if you meet these requirements:

-Have a diagnosis of Alzheimer's disease or probable dementia with Lewy Bodies

-Have a friend, family member, or caretaker who is able and willing to answer questions about you

-Have at least 8 years of education

 

COMPENSATION

Volunteers who complete this study will receive up to $250 in appreciation for their time and participation.

 

CONTACT

Study Contact: Sarah Payne | 206.277.1379

Study PI: Debby Tsuang, MD, Professor, UW Psychiatry & Behavioral Sciences/ Leader of the Dementia with Lewy Body Consortium Study site at the VA Puget Sound Health Care Center/UW


The Dementia with Lewy Bodies Consortium Study

The Dementia with Lewy Bodies Consortium Study

The purpose of the Dementia with Lewy Bodies Consortium is to develop a collection of samples from individuals diagnosed with dementia with lewy bodies (DLB), dementia with lewy bodies/mild cognitive impairment (MCI), or Parkinson's disease dementia who will be followed over time. The consortium will collect detailed clinical information, biospecimens, and imaging data. Led by top leaders in the field, this consortium will fill the gap in resources available for biomarker development in Lewy Body Dementia and promote additional future research by having a readily available subject sample. 

 

You may qualify for this study if you:

-Have a diagnosis of probable dementia with lewy body/MCI or Parkinson's disease dementia

-Have a study partner who is able and willing to comply with required study procedures

-Have at least eight years of education

The study doctor will also check for other medical conditions or reasons that might prevent you from participating in the study

 

Study Leader: Debby Tsuang, MD, Professor, UW Psychiatry & Behavioral Sciences/ Leader of the Dementia with Lewy Body Consortium Study site at the VA Puget Sound Health Care Center/UW

Seattle Study Contact: Sarah Payne | 206.277.1379

For More Information

The Remote Cog Study

Researchers at the VA Puget Sound Hospital in Seattle are seeking volunteers for the Remote Cog Study. Black Americans often miss out on early care that can help with memory and mental health changes. We hope to learn how to spot these changes earlier in Black Americans.

We are enrolling Black Americans who are age 65+, concerned about their memory, and interested in a 10-week research study from the comfort of their own homes that includes: 

 

Answering health-related questions using paper, a telephone, and a mobile device 

Using several devices at home, including a wristwatch, thermometer, and blood pressure monitor 

Providing a blood sample 

 

Learn more

Please contact us at (206) 277-1379 for more information.

The lead researcher of this study is Dr. Debby Tsuang at S182 GRECC, VA Puget Sound, 1660 S. Columbian Way, Seattle WA 98108.

For More Information

AHEAD Study (BAN2401)

The AHEAD Study is testing whether an investigational treatment can lower people’s risk of memory loss due to Alzheimer’s disease.

Researchers have learned that changes in the brains of people with Alzheimer’s disease start as many as 20 years before they notice symptoms like memory problems. During those two decades, a protein in the brain called “amyloid” builds up in people who go on to have memory problems because of Alzheimer’s disease. While not all people with amyloid in their brain will develop memory problems, we know that the people who do are at a higher risk for developing the disease.

The study is funded by the National Institutes of Health, in partnership with the pharmaceutical company Eisai. It is being conducted by the NIH-funded Alzheimer’s Clinical Trial Consortium (ACTC), a network of leading academic Alzheimer’s research centers.

 

WHAT IS THE AHEAD STUDY?

The AHEAD Study is comprised of two different clinical trials testing the same investigational drug (known as BAN2401 (lecanemab)) in people who may be at risk for memory problems. Participants will receive personalized study treatment, instead of a one-size-fits-all approach. Study participants are enrolled in one of two AHEAD trials based on the level of amyloid in their brain: 

Participants with intermediate amyloid levels take part in the AHEAD A-3 trial—the first ever trial aimed at what may be the earliest signs of Alzheimer’s disease. Participants in the AHEAD A-3 trial will receive BAN2401 (lecanemab) once every 4 weeks for 4 years.

Participants with elevated amyloid levels take part in the AHEAD A-45 trial. Participants in the AHEAD A-45 trial will receive BAN2401 (lecanemab) once every 2 weeks for about 2 years and then once every 4 weeks for the remainder of the study.

Participants in both trials will receive intravenous (IV) infusions of BAN2401 (lecanemab), tailored to their risk of developing memory loss, or a placebo, an inactive substance designed to mimic the appearance of the drug. The infusion takes approximately 60 minutes.

At different points in the study, participants have a PET scan (or Positron Emission Tomography brain scan), to look at amyloid and tau (another protein) in their brain. This helps the participants and researchers track their health and this is the first study of its kind to use PET scans to measure amyloid and tau in all participants. The PET scan takes pictures of participants’ brains, allowing researchers to see and track changes in amyloid and tau levels.

 

ELIGIBILITY

Participants Eligible for the AHEAD Study:

Are healthy adults ages 55-80.

Have not been diagnosed with Alzheimer’s disease or another dementia.

Have a study partner, either a close relative or friend, who will participate in one study visit per year.

Have elevated or intermediate levels of amyloid in their brain, found by imaging as part of the study.

Learn More

 

PARTICIPATION REQUIREMENTS

Learn about what you will do as a study participant

 

UW ADRC Site Contact:

Kinsey Chapman

kinseyc@uw.edu

206-744-0446

 

UW ADRC Site PI:

Darla Chapman, Clinical Trials Coordinator and Clinician, ADRC

For More Information

MAP: Metformin in Alzheimer’s Dementia Prevention

 JOIN US IN OUR FIGHT TO HELP PREVENT DEMENTIA 

MAP: Metformin in Alzheimer's Dementia Prevention is a research study looking at an existing drug used for diabetes prevention. The study tests if this drug can help prevent a decline in memory and thinking abilities for people with mild memory problems. It is a randomized study in which you will take either metformin (Glucophage® XR) or a placebo. 

Randomized means you will have an equal opportunity of getting the study drug or placebo. A placebo is a pill that looks the same as the study drug, but has no medicine. 

There will be no charge to you for the study drug or study visits. 

Taking part in this study is completely voluntary. We appreciate your participation. 

MAP is a multi-center study, where people can take part in the study at 11 locations throughout the United States. It is funded by the National Institutes of Health (NIH) through the National Institute on Aging (NIA). Our researchers are experienced in running research studies. They are also experts in the field of memory loss, dementia, and Alzheimer’s disease. We invite you to join us in our search for treatments to improve the lives of those with memory problems due to Alzheimer’s disease. 

 

 You may be able to join if: 

  • you are 55-90 years old, 
  • you or your loved ones have noticed some changes in your memory, and 
  • you are not already being treated for diabetes or dementia 

 

Potential benefits:

  • You will receive some of your blood test results. We can also share these results with your healthcare provider.
  • Your participation may improve the prevention of dementia for future generations.

 

Taking part in MAP is voluntary and will not affect the care you receive.  If you decide to join, you will be compensated for your time. You may earn up to $850 for completing all study-related visits. 

 

To learn more about the MAP study, please contact our local UW study coordinator: 

Hanson Research Team 

(206) 744-1851 or (206) 897-5393

hansonlab@uw.edu 

 

Visit us at: https://www.iths.org/participate/metformin-in-alzheimers-dementia-prevention-map/


PoND: Prazosin and CSF Biomarkers in Aging, MCI and AD

We are seeking healthy, medically stable volunteers over the age of 45 who do not have memory problems for a new approach to preventing Alzheimer’s and other dementias.

Details

  • The study includes an assessment of your physical and mental health.
  • You will receive prazosin (a pill used for posttraumatic stress disorder and high blood pressure).
  • The study will take about 14 hours, spread over roughly 9 visits during a 3-month period.
  • These visits will be at the Seattle VA.
  • You will be compensated for each of your visits, with the total compensation for the study amounting to $750 to $825.

Key Researcher: The PI of this study is Murray Raskind at S-116-MIRECC, 1660 S. Columbian Way, Seattle, WA  98108.

Study Contact: 206.277.1491 or 1.800.329.8387 ext. 1491 

For More Information

Prazosin and CSF Biomarkers in mTBI

Prazosin and CSF Biomarkers in mTBI

Mild traumatic brain injury (mTBI) from explosions is the "signature injury" of Veterans who have deployed to the wars in Afghanistan and Iraq. Although the immediate effects of a single mTBI usually resolve over days or weeks, multiple mTBIs can lead to both persistent symptoms and, years later, to two fatal progressive brain diseases, chronic traumatic encephalopathy and Alzheimer's disease. It is believed that these diseases are caused by nerve damaging chemicals called tau and beta amyloid produced by the brain but which are not removed from the brain in a normal manner in persons with mTBIs. The investigators will determine in Veterans who experienced mTBIs whether a clinically available drug called prazosin increases removal of tau and beta amyloid from the brain. This will be accomplished by seeing if prazosin reduces the amount of tau and beta amyloid in the spinal fluid that surrounds the brain. If the investigators find such reductions, prazosin will be evaluated as a preventative treatment in future studies. (from Clinical Trials.gov)

 

Key researcher: Murray A Raskind, MD, VA Puget Sound Health Care System Seattle Division, Seattle, WA

Study Contacts: Rebecca C Hendrickson, MD | Rebecca.Hendrickson@va.gov | 206-277-5054

                         Hollie A Holmes | hollie.holmes@va.gov | (206) 277-6207

Trial Description on clinicaltrials.gov

For More Information

RethinkAlz (simufilam)

RethinkALZ is a a new clinical trial for Alzheimer's Disease. The purpose of this trial is to determine if a new, twice-a-day, oral drug candidate called simufilam is safe and effective in slowing down the progression of mild-to-moderate Alzheimer’s disease. Simufilam is an investigational drug candidate that has not been approved by the US Food and Drug Administration (FDA), or any regulatory agency, for the treatment of any condition.

Simufilam (formerly known as PTI-125) is an investigational drug that represents an entirely new approach to treat Alzheimer’s disease.

Importantly, we do not seek to clear amyloid out of the brain. Our science is based on stabilizing a critical protein in the brain.

Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. (For a video and description of the drug, please visit: https://www.cassavasciences.com/simufilam)

 

Participants who are eligible for the RethinkALZ study must:

  • Be ages 50 to 87 years old
  • Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease
  • Have a gradual change in memory for six months or more
  • Have a family member or loved one who can be available as a study partner during the entire study
  • Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection  

Other criteria will apply.

The RethinkALZ study is now open to qualifying participants. The trial lasts 52 weeks. If you enroll into this trial, you will receive either the oral study drug or placebo twice a day. A placebo looks like the study drug but has no impact on the person taking it. There is no cost to the patient to participate in the RethinkALZ trial or for any of the study-related procedures. No hospitalization is required. You may be compensated for your time and travel for each clinical study appointment.

To learn more about the RethinkALZ study, please contact our local UW study coordinator: 

 

Megan Zdancewic

Email: meganz2@uw.edu

Phone: 206-823-4847

 

UW ADRC Site PI:

Charles Bernick, MD, MPH, Director of Clinical Trials, MBWC


Novo Nordisk Evoke +

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

If you or someone you love is increasingly becoming forgetful, experiencing difficulties in planning and problem solving, or getting lost in familiar places, these could be signs of early Alzheimer’s disease. 

Contact us today to find out more about the evoke+ clinical study. 

Consider participating in the study if: 

You (may) have early Alzheimer’s disease. 

You are between 55 and 85 years old. 

You have a study partner (a next of kin or someone you have a close relationship with), who is willing to take part in the study and share information about you. 

The study doctor will explain any potential risks to you and describe the study procedures before you decide whether to join the study. 

If eligible, you will be one of over 3500 participants worldwide on this 3-year journey and will receive regular clinic visits, health checkups, and medical testing. You will get access to expert guidance and facilities during the study. 

 

UW ADRC Contact:

Kristin Farris, UW Study Coordinator

Phone 206-897-6797

Email kmfarris@uw.edu


RethinkAlz (simufilam)

RethinkALZ is a a new clinical trial for Alzheimer's Disease. The purpose of this trial is to determine if a new, twice-a-day, oral drug candidate called simufilam is safe and effective in slowing down the progression of mild-to-moderate Alzheimer’s disease. Simufilam is an investigational drug candidate that has not been approved by the US Food and Drug Administration (FDA), or any regulatory agency, for the treatment of any condition.

Simufilam (formerly known as PTI-125) is an investigational drug that represents an entirely new approach to treat Alzheimer’s disease.

Importantly, we do not seek to clear amyloid out of the brain. Our science is based on stabilizing a critical protein in the brain.

Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. (For a video and description of the drug, please visit: https://www.cassavasciences.com/simufilam)

 

Participants who are eligible for the RethinkALZ study must:

  • Be ages 50 to 87 years old
  • Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease
  • Have a gradual change in memory for six months or more
  • Have a family member or loved one who can be available as a study partner during the entire study
  • Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection  

Other criteria will apply.

The RethinkALZ study is now open to qualifying participants. The trial lasts 52 weeks. If you enroll into this trial, you will receive either the oral study drug or placebo twice a day. A placebo looks like the study drug but has no impact on the person taking it. There is no cost to the patient to participate in the RethinkALZ trial or for any of the study-related procedures. No hospitalization is required. You may be compensated for your time and travel for each clinical study appointment.

To learn more about the RethinkALZ study, please contact our local UW study coordinator: 

 

Megan Zdancewic

Email: meganz2@uw.edu

Phone: 206-823-4847

 

UW ADRC Site PI:

Charles Bernick, MD, MPH, Director of Clinical Trials, MBWC


ADRC Clinical Core

Who we are

The UW Alzheimer’s Disease Research Center (ADRC) is part of a nationwide network of research centers funded by the National Institute on Aging to learn more about Alzheimer’s disease and related dementias.  We are exploring innovative approaches to diagnosis, treatment, and disease prevention by partnering with people who have normal memory and thinking and those who have memory concerns or are living with dementia.  

In order to learn more about diseases that cause memory loss and dementia, we are looking for volunteers from a variety of ethnic backgrounds and ages who are willing to participate in research.  It is important to study a diverse group of people so that the information we learn will benefit everyone.

 

Who we are seeking

The UW ADRC is interested in partnering with:

-People from underrepresented groups, such as African Americans, Hispanics, American Indians and Alaskan Natives.  

-People diagnosed with memory and thinking (cognitive) changes by their medical provider, especially a diagnosis of Mild Cognitive Impairment

-We are also interested in partnering with people from any ethnic background who are 85 years or older and who do not have concerns about their memory or thinking. 

 

What to expect at a UW ADRC research visit

This study involves a yearly visit during which volunteers complete tests of their memory and thinking, have a brief physical and neurological examination, and answer questions about their medical history, memory, mood, and ability to perform daily activities. Volunteers must also have a study partner who knows them well and would notice changes in their memory, mood or ability to perform daily activities.  

We may also ask some volunteers for a blood or cerebral spinal fluid sample in order to learn more about how our bodies change in response to normal aging and dementia.

To learn more about participating, contact: UW ADRC at 206-744-0588,  uwadrc@uw.edu

For More Information

Late Onset Alzheimer’s Disease Study NIA- LOAD

We are studying families with histories of dementia to understand the genetic components behind Alzheimer’s disease. 

 

You may qualify for this study if you meet these requirements: 

-Have living family member(s) with a diagnosis of Alzheimer’s disease or related dementia

-Have a friend, family member, or caretaker who is able and willing to answer questions about you 

-Are willing to be contacted every  1-2 years to complete memory testing and an interview, both of which can be completed over the phone

 

Contact

For more information, please contact the Research Coordinator at 206.277.1024

 

Study Leader

Debby Tsuang, MD, Professor, Psychiatry & Behavioral Sciences/ Adjunct Professor, Epidemiology
Director, GRECC, VISN-20 Geriatric Research, Education, and Clinical Center
Psychiatrist, Clinical Core,  ADRC

For More Information

Lipid MRI Study

Dr. Angela Hanson, MD at the University of Washington is enrolling people for a NIH funded study to test how two simple nutrients, sugar and fat, can affect your memory, brain (via MRI Scan) and blood biomarkers. The Lipid MRI study involves non-invasive MRI imaging to see how a risk gene for Alzheimer’s disease, APOE4, affects brain blood flow after a high fat drink. With this study, we hope to understand what parts of the brain are most affected by a high fat meal.

 

YOU MAY BE ELIGIBLE IF

• You are age 55 or older

• You do not have Alzheimer's disease or dementia already

• You are not currently taking medication for diabetes

 

PARTICIPANTS WILL RECEIVE

• Information about dementia prevention

• Participants will be compensated for their time.

 

ABOUT

-The study involves one initial screening visit and one study visit. For both visits, we ask participants to fast in the morning (water and medications are still okay to take). Study participants will be compensated for their time.

-The screening visit takes place at the University of Washington South Lake Union campus and involves obtaining in-person consent, vitals, blood draws through an IV, a brief memory test, an oral glucose tolerance test, and a DEXA scan to measure body composition. The visit will last about 3.5 hours.

-The final study visit takes place at the University of Washington main campus. This visit involves blood draws through an IV, drinking dairy cream, two MRI scans, and cognitive testing on an iPad. The visit will last about 5 hours.

 

Contact: Hanson Research Team

Email: hansonlab@uw.edu

Phone: 206-897-5393


Technology for Early Dementia Diagnosis

Researchers at the VA Geriatric Research, Education, and Clinical Centers are studying wearable technologies that may be useful to help diagnose Alzheimer's disease and dementia with Lewy bodies.

ELIGIBILITY

You may qualify for this study if you meet these requirements:

-Have a diagnosis of Alzheimer's disease or probable dementia with Lewy Bodies

-Have a friend, family member, or caretaker who is able and willing to answer questions about you

-Have at least 8 years of education

 

COMPENSATION

Volunteers who complete this study will receive up to $250 in appreciation for their time and participation.

 

CONTACT

Study Contact: Sarah Payne | 206.277.1379

Study PI: Debby Tsuang, MD, Professor, UW Psychiatry & Behavioral Sciences/ Leader of the Dementia with Lewy Body Consortium Study site at the VA Puget Sound Health Care Center/UW


The Dementia with Lewy Bodies Consortium Study

The Dementia with Lewy Bodies Consortium Study

The purpose of the Dementia with Lewy Bodies Consortium is to develop a collection of samples from individuals diagnosed with dementia with lewy bodies (DLB), dementia with lewy bodies/mild cognitive impairment (MCI), or Parkinson's disease dementia who will be followed over time. The consortium will collect detailed clinical information, biospecimens, and imaging data. Led by top leaders in the field, this consortium will fill the gap in resources available for biomarker development in Lewy Body Dementia and promote additional future research by having a readily available subject sample. 

 

You may qualify for this study if you:

-Have a diagnosis of probable dementia with lewy body/MCI or Parkinson's disease dementia

-Have a study partner who is able and willing to comply with required study procedures

-Have at least eight years of education

The study doctor will also check for other medical conditions or reasons that might prevent you from participating in the study

 

Study Leader: Debby Tsuang, MD, Professor, UW Psychiatry & Behavioral Sciences/ Leader of the Dementia with Lewy Body Consortium Study site at the VA Puget Sound Health Care Center/UW

Seattle Study Contact: Sarah Payne | 206.277.1379

For More Information

AHEAD Study (BAN2401)

The AHEAD Study is testing whether an investigational treatment can lower people’s risk of memory loss due to Alzheimer’s disease.

Researchers have learned that changes in the brains of people with Alzheimer’s disease start as many as 20 years before they notice symptoms like memory problems. During those two decades, a protein in the brain called “amyloid” builds up in people who go on to have memory problems because of Alzheimer’s disease. While not all people with amyloid in their brain will develop memory problems, we know that the people who do are at a higher risk for developing the disease.

The study is funded by the National Institutes of Health, in partnership with the pharmaceutical company Eisai. It is being conducted by the NIH-funded Alzheimer’s Clinical Trial Consortium (ACTC), a network of leading academic Alzheimer’s research centers.

 

WHAT IS THE AHEAD STUDY?

The AHEAD Study is comprised of two different clinical trials testing the same investigational drug (known as BAN2401 (lecanemab)) in people who may be at risk for memory problems. Participants will receive personalized study treatment, instead of a one-size-fits-all approach. Study participants are enrolled in one of two AHEAD trials based on the level of amyloid in their brain: 

Participants with intermediate amyloid levels take part in the AHEAD A-3 trial—the first ever trial aimed at what may be the earliest signs of Alzheimer’s disease. Participants in the AHEAD A-3 trial will receive BAN2401 (lecanemab) once every 4 weeks for 4 years.

Participants with elevated amyloid levels take part in the AHEAD A-45 trial. Participants in the AHEAD A-45 trial will receive BAN2401 (lecanemab) once every 2 weeks for about 2 years and then once every 4 weeks for the remainder of the study.

Participants in both trials will receive intravenous (IV) infusions of BAN2401 (lecanemab), tailored to their risk of developing memory loss, or a placebo, an inactive substance designed to mimic the appearance of the drug. The infusion takes approximately 60 minutes.

At different points in the study, participants have a PET scan (or Positron Emission Tomography brain scan), to look at amyloid and tau (another protein) in their brain. This helps the participants and researchers track their health and this is the first study of its kind to use PET scans to measure amyloid and tau in all participants. The PET scan takes pictures of participants’ brains, allowing researchers to see and track changes in amyloid and tau levels.

 

ELIGIBILITY

Participants Eligible for the AHEAD Study:

Are healthy adults ages 55-80.

Have not been diagnosed with Alzheimer’s disease or another dementia.

Have a study partner, either a close relative or friend, who will participate in one study visit per year.

Have elevated or intermediate levels of amyloid in their brain, found by imaging as part of the study.

Learn More

 

PARTICIPATION REQUIREMENTS

Learn about what you will do as a study participant

 

UW ADRC Site Contact:

Kinsey Chapman

kinseyc@uw.edu

206-744-0446

 

UW ADRC Site PI:

Darla Chapman, Clinical Trials Coordinator and Clinician, ADRC

For More Information

All Studies and Trials

ADRC Clinical Core

Who we are

The UW Alzheimer’s Disease Research Center (ADRC) is part of a nationwide network of research centers funded by the National Institute on Aging to learn more about Alzheimer’s disease and related dementias.  We are exploring innovative approaches to diagnosis, treatment, and disease prevention by partnering with people who have normal memory and thinking and those who have memory concerns or are living with dementia.  

In order to learn more about diseases that cause memory loss and dementia, we are looking for volunteers from a variety of ethnic backgrounds and ages who are willing to participate in research.  It is important to study a diverse group of people so that the information we learn will benefit everyone.

 

Who we are seeking

The UW ADRC is interested in partnering with:

-People from underrepresented groups, such as African Americans, Hispanics, American Indians and Alaskan Natives.  

-People diagnosed with memory and thinking (cognitive) changes by their medical provider, especially a diagnosis of Mild Cognitive Impairment

-We are also interested in partnering with people from any ethnic background who are 85 years or older and who do not have concerns about their memory or thinking. 

 

What to expect at a UW ADRC research visit

This study involves a yearly visit during which volunteers complete tests of their memory and thinking, have a brief physical and neurological examination, and answer questions about their medical history, memory, mood, and ability to perform daily activities. Volunteers must also have a study partner who knows them well and would notice changes in their memory, mood or ability to perform daily activities.  

We may also ask some volunteers for a blood or cerebral spinal fluid sample in order to learn more about how our bodies change in response to normal aging and dementia.

To learn more about participating, contact: UW ADRC at 206-744-0588,  uwadrc@uw.edu

For More Information

AHEAD Study (BAN2401)

The AHEAD Study is testing whether an investigational treatment can lower people’s risk of memory loss due to Alzheimer’s disease.

Researchers have learned that changes in the brains of people with Alzheimer’s disease start as many as 20 years before they notice symptoms like memory problems. During those two decades, a protein in the brain called “amyloid” builds up in people who go on to have memory problems because of Alzheimer’s disease. While not all people with amyloid in their brain will develop memory problems, we know that the people who do are at a higher risk for developing the disease.

The study is funded by the National Institutes of Health, in partnership with the pharmaceutical company Eisai. It is being conducted by the NIH-funded Alzheimer’s Clinical Trial Consortium (ACTC), a network of leading academic Alzheimer’s research centers.

 

WHAT IS THE AHEAD STUDY?

The AHEAD Study is comprised of two different clinical trials testing the same investigational drug (known as BAN2401 (lecanemab)) in people who may be at risk for memory problems. Participants will receive personalized study treatment, instead of a one-size-fits-all approach. Study participants are enrolled in one of two AHEAD trials based on the level of amyloid in their brain: 

Participants with intermediate amyloid levels take part in the AHEAD A-3 trial—the first ever trial aimed at what may be the earliest signs of Alzheimer’s disease. Participants in the AHEAD A-3 trial will receive BAN2401 (lecanemab) once every 4 weeks for 4 years.

Participants with elevated amyloid levels take part in the AHEAD A-45 trial. Participants in the AHEAD A-45 trial will receive BAN2401 (lecanemab) once every 2 weeks for about 2 years and then once every 4 weeks for the remainder of the study.

Participants in both trials will receive intravenous (IV) infusions of BAN2401 (lecanemab), tailored to their risk of developing memory loss, or a placebo, an inactive substance designed to mimic the appearance of the drug. The infusion takes approximately 60 minutes.

At different points in the study, participants have a PET scan (or Positron Emission Tomography brain scan), to look at amyloid and tau (another protein) in their brain. This helps the participants and researchers track their health and this is the first study of its kind to use PET scans to measure amyloid and tau in all participants. The PET scan takes pictures of participants’ brains, allowing researchers to see and track changes in amyloid and tau levels.

 

ELIGIBILITY

Participants Eligible for the AHEAD Study:

Are healthy adults ages 55-80.

Have not been diagnosed with Alzheimer’s disease or another dementia.

Have a study partner, either a close relative or friend, who will participate in one study visit per year.

Have elevated or intermediate levels of amyloid in their brain, found by imaging as part of the study.

Learn More

 

PARTICIPATION REQUIREMENTS

Learn about what you will do as a study participant

 

UW ADRC Site Contact:

Kinsey Chapman

kinseyc@uw.edu

206-744-0446

 

UW ADRC Site PI:

Darla Chapman, Clinical Trials Coordinator and Clinician, ADRC

For More Information

Late Onset Alzheimer’s Disease Study NIA- LOAD

We are studying families with histories of dementia to understand the genetic components behind Alzheimer’s disease. 

 

You may qualify for this study if you meet these requirements: 

-Have living family member(s) with a diagnosis of Alzheimer’s disease or related dementia

-Have a friend, family member, or caretaker who is able and willing to answer questions about you 

-Are willing to be contacted every  1-2 years to complete memory testing and an interview, both of which can be completed over the phone

 

Contact

For more information, please contact the Research Coordinator at 206.277.1024

 

Study Leader

Debby Tsuang, MD, Professor, Psychiatry & Behavioral Sciences/ Adjunct Professor, Epidemiology
Director, GRECC, VISN-20 Geriatric Research, Education, and Clinical Center
Psychiatrist, Clinical Core,  ADRC

For More Information

Latino Caregiver Research Study

Latino Caregiver Research Study (Spanish/English translations below)

 

Investigadores de la Universidad de Washington están desarrollando un programa para apoyar a cuidadores de familiares con enfermedad de Alzheimer o demencias relacionadas. Están interesados en hablar con familiares o amigos cercanos que son cuidadores de personas con demencia que tengan problemas de comportamiento como depresión, discusiones o rehusarse a bañarse y vestirse. 

Su participación es voluntaria y confidencial.

 

Buscamos personas que cumplan los siguientes requisitos:

-Se identifique como Hispano/Latino

-Cuiden a un familiar o amigo cercano con diagnóstico de enfermedad de Alzheimer u otra demencia r-elacionada

-Su familiar tiene problemas de comportamiento

 

Para participar necesita:

-Completar una encuesta (10 minutos) y participar en una entrevista por teléfono o Zoom.

-Recibirá una compensación de $45 en agradecimiento a su tiempo

 

Para participar en el estudio o recibir más información, favor de comunicarse con la Miriana Duran: mdp19@uw.edu ó 206-221-6206

 

______

Researchers at the University of Washington are developing a program to support family (or close friend) caregivers of individuals with Alzheimer’s disease or related dementia. They are interested in speaking with family caregivers that are caring for individuals experiencing behavior issues such as trying to leave the house, arguing, or refusing to bathe or get dressed.

Research is always voluntary.

 

This study might be a good fit for you if you:

-Identify as Hispanic/Latino

-Take care of a family member or close friend diagnosed with Alzheimer’s disease or other dementia

- Have a family member or close friend who is experiencing behavior issues

 

If you decide to take part in the research study:

-You will need to complete a 10 minute survey and a 1 hour interview by phone or Zoom.

-You will receive $45 to thank you for your time and effort

 

To learn more about the study, please contact Miriana Duran: mdp19@uw.edu or 206-221-6206

Lipid MRI Study

Dr. Angela Hanson, MD at the University of Washington is enrolling people for a NIH funded study to test how two simple nutrients, sugar and fat, can affect your memory, brain (via MRI Scan) and blood biomarkers. The Lipid MRI study involves non-invasive MRI imaging to see how a risk gene for Alzheimer’s disease, APOE4, affects brain blood flow after a high fat drink. With this study, we hope to understand what parts of the brain are most affected by a high fat meal.

 

YOU MAY BE ELIGIBLE IF

• You are age 55 or older

• You do not have Alzheimer's disease or dementia already

• You are not currently taking medication for diabetes

 

PARTICIPANTS WILL RECEIVE

• Information about dementia prevention

• Participants will be compensated for their time.

 

ABOUT

-The study involves one initial screening visit and one study visit. For both visits, we ask participants to fast in the morning (water and medications are still okay to take). Study participants will be compensated for their time.

-The screening visit takes place at the University of Washington South Lake Union campus and involves obtaining in-person consent, vitals, blood draws through an IV, a brief memory test, an oral glucose tolerance test, and a DEXA scan to measure body composition. The visit will last about 3.5 hours.

-The final study visit takes place at the University of Washington main campus. This visit involves blood draws through an IV, drinking dairy cream, two MRI scans, and cognitive testing on an iPad. The visit will last about 5 hours.

 

Contact: Hanson Research Team

Email: hansonlab@uw.edu

Phone: 206-897-5393

MAP: Metformin in Alzheimer’s Dementia Prevention

 JOIN US IN OUR FIGHT TO HELP PREVENT DEMENTIA 

MAP: Metformin in Alzheimer's Dementia Prevention is a research study looking at an existing drug used for diabetes prevention. The study tests if this drug can help prevent a decline in memory and thinking abilities for people with mild memory problems. It is a randomized study in which you will take either metformin (Glucophage® XR) or a placebo. 

Randomized means you will have an equal opportunity of getting the study drug or placebo. A placebo is a pill that looks the same as the study drug, but has no medicine. 

There will be no charge to you for the study drug or study visits. 

Taking part in this study is completely voluntary. We appreciate your participation. 

MAP is a multi-center study, where people can take part in the study at 11 locations throughout the United States. It is funded by the National Institutes of Health (NIH) through the National Institute on Aging (NIA). Our researchers are experienced in running research studies. They are also experts in the field of memory loss, dementia, and Alzheimer’s disease. We invite you to join us in our search for treatments to improve the lives of those with memory problems due to Alzheimer’s disease. 

 

 You may be able to join if: 

  • you are 55-90 years old, 
  • you or your loved ones have noticed some changes in your memory, and 
  • you are not already being treated for diabetes or dementia 

 

Potential benefits:

  • You will receive some of your blood test results. We can also share these results with your healthcare provider.
  • Your participation may improve the prevention of dementia for future generations.

 

Taking part in MAP is voluntary and will not affect the care you receive.  If you decide to join, you will be compensated for your time. You may earn up to $850 for completing all study-related visits. 

 

To learn more about the MAP study, please contact our local UW study coordinator: 

Hanson Research Team 

(206) 744-1851 or (206) 897-5393

hansonlab@uw.edu 

 

Visit us at: https://www.iths.org/participate/metformin-in-alzheimers-dementia-prevention-map/

Meal and Memory Study

APOE genotype and diet influences on Alzheimer's biomarkers

We are learning more and more about the risks for Alzheimer's disease every year, and that includes learning what foods are best at promoting brain health. It might be more complicated than 'this food is good or bad.' Dr. Angela Hanson, a geriatric physician at the University of Washington, is conducting a study that examines how a risk gene for Alzheimer's disease might affect people's memory and metabolic responses to different meals. Her preliminary work showed that people who carry the gene APOE4 (E4) responded differently to different Alzheimer's treatments and diets, compared to people who did not carry this gene. Dr. Hanson plans to study this further with the "Meal and Memory Study” in adults age 55 and older who do not have dementia. 

 

Eligibility: Participants may be men or women, ages 55 and older. People who have known dementia, or known diabetes, are not eligible.

 

Key researcher:  Angela Hanson, MD

Study Contact: Angela Hanson at 206-897-5393 or hansonaj@uw.edu

For More Information

Novo Nordisk Evoke +

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

If you or someone you love is increasingly becoming forgetful, experiencing difficulties in planning and problem solving, or getting lost in familiar places, these could be signs of early Alzheimer’s disease. 

Contact us today to find out more about the evoke+ clinical study. 

Consider participating in the study if: 

You (may) have early Alzheimer’s disease. 

You are between 55 and 85 years old. 

You have a study partner (a next of kin or someone you have a close relationship with), who is willing to take part in the study and share information about you. 

The study doctor will explain any potential risks to you and describe the study procedures before you decide whether to join the study. 

If eligible, you will be one of over 3500 participants worldwide on this 3-year journey and will receive regular clinic visits, health checkups, and medical testing. You will get access to expert guidance and facilities during the study. 

 

UW ADRC Contact:

Kristin Farris, UW Study Coordinator

Phone 206-897-6797

Email kmfarris@uw.edu

PoND: Prazosin and CSF Biomarkers in Aging, MCI and AD

We are seeking healthy, medically stable volunteers over the age of 45 who do not have memory problems for a new approach to preventing Alzheimer’s and other dementias.

Details

  • The study includes an assessment of your physical and mental health.
  • You will receive prazosin (a pill used for posttraumatic stress disorder and high blood pressure).
  • The study will take about 14 hours, spread over roughly 9 visits during a 3-month period.
  • These visits will be at the Seattle VA.
  • You will be compensated for each of your visits, with the total compensation for the study amounting to $750 to $825.

Key Researcher: The PI of this study is Murray Raskind at S-116-MIRECC, 1660 S. Columbian Way, Seattle, WA  98108.

Study Contact: 206.277.1491 or 1.800.329.8387 ext. 1491 

For More Information

Prazosin and CSF Biomarkers in mTBI

Prazosin and CSF Biomarkers in mTBI

Mild traumatic brain injury (mTBI) from explosions is the "signature injury" of Veterans who have deployed to the wars in Afghanistan and Iraq. Although the immediate effects of a single mTBI usually resolve over days or weeks, multiple mTBIs can lead to both persistent symptoms and, years later, to two fatal progressive brain diseases, chronic traumatic encephalopathy and Alzheimer's disease. It is believed that these diseases are caused by nerve damaging chemicals called tau and beta amyloid produced by the brain but which are not removed from the brain in a normal manner in persons with mTBIs. The investigators will determine in Veterans who experienced mTBIs whether a clinically available drug called prazosin increases removal of tau and beta amyloid from the brain. This will be accomplished by seeing if prazosin reduces the amount of tau and beta amyloid in the spinal fluid that surrounds the brain. If the investigators find such reductions, prazosin will be evaluated as a preventative treatment in future studies. (from Clinical Trials.gov)

 

Key researcher: Murray A Raskind, MD, VA Puget Sound Health Care System Seattle Division, Seattle, WA

Study Contacts: Rebecca C Hendrickson, MD | Rebecca.Hendrickson@va.gov | 206-277-5054

                         Hollie A Holmes | hollie.holmes@va.gov | (206) 277-6207

Trial Description on clinicaltrials.gov

For More Information

RethinkAlz (simufilam)

RethinkALZ is a a new clinical trial for Alzheimer's Disease. The purpose of this trial is to determine if a new, twice-a-day, oral drug candidate called simufilam is safe and effective in slowing down the progression of mild-to-moderate Alzheimer’s disease. Simufilam is an investigational drug candidate that has not been approved by the US Food and Drug Administration (FDA), or any regulatory agency, for the treatment of any condition.

Simufilam (formerly known as PTI-125) is an investigational drug that represents an entirely new approach to treat Alzheimer’s disease.

Importantly, we do not seek to clear amyloid out of the brain. Our science is based on stabilizing a critical protein in the brain.

Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. (For a video and description of the drug, please visit: https://www.cassavasciences.com/simufilam)

 

Participants who are eligible for the RethinkALZ study must:

  • Be ages 50 to 87 years old
  • Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease
  • Have a gradual change in memory for six months or more
  • Have a family member or loved one who can be available as a study partner during the entire study
  • Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection  

Other criteria will apply.

The RethinkALZ study is now open to qualifying participants. The trial lasts 52 weeks. If you enroll into this trial, you will receive either the oral study drug or placebo twice a day. A placebo looks like the study drug but has no impact on the person taking it. There is no cost to the patient to participate in the RethinkALZ trial or for any of the study-related procedures. No hospitalization is required. You may be compensated for your time and travel for each clinical study appointment.

To learn more about the RethinkALZ study, please contact our local UW study coordinator: 

 

Megan Zdancewic

Email: meganz2@uw.edu

Phone: 206-823-4847

 

UW ADRC Site PI:

Charles Bernick, MD, MPH, Director of Clinical Trials, MBWC

Technology for Early Dementia Diagnosis

Researchers at the VA Geriatric Research, Education, and Clinical Centers are studying wearable technologies that may be useful to help diagnose Alzheimer's disease and dementia with Lewy bodies.

ELIGIBILITY

You may qualify for this study if you meet these requirements:

-Have a diagnosis of Alzheimer's disease or probable dementia with Lewy Bodies

-Have a friend, family member, or caretaker who is able and willing to answer questions about you

-Have at least 8 years of education

 

COMPENSATION

Volunteers who complete this study will receive up to $250 in appreciation for their time and participation.

 

CONTACT

Study Contact: Sarah Payne | 206.277.1379

Study PI: Debby Tsuang, MD, Professor, UW Psychiatry & Behavioral Sciences/ Leader of the Dementia with Lewy Body Consortium Study site at the VA Puget Sound Health Care Center/UW

The Dementia with Lewy Bodies Consortium Study

The Dementia with Lewy Bodies Consortium Study

The purpose of the Dementia with Lewy Bodies Consortium is to develop a collection of samples from individuals diagnosed with dementia with lewy bodies (DLB), dementia with lewy bodies/mild cognitive impairment (MCI), or Parkinson's disease dementia who will be followed over time. The consortium will collect detailed clinical information, biospecimens, and imaging data. Led by top leaders in the field, this consortium will fill the gap in resources available for biomarker development in Lewy Body Dementia and promote additional future research by having a readily available subject sample. 

 

You may qualify for this study if you:

-Have a diagnosis of probable dementia with lewy body/MCI or Parkinson's disease dementia

-Have a study partner who is able and willing to comply with required study procedures

-Have at least eight years of education

The study doctor will also check for other medical conditions or reasons that might prevent you from participating in the study

 

Study Leader: Debby Tsuang, MD, Professor, UW Psychiatry & Behavioral Sciences/ Leader of the Dementia with Lewy Body Consortium Study site at the VA Puget Sound Health Care Center/UW

Seattle Study Contact: Sarah Payne | 206.277.1379

For More Information

The Remote Cog Study

Researchers at the VA Puget Sound Hospital in Seattle are seeking volunteers for the Remote Cog Study. Black Americans often miss out on early care that can help with memory and mental health changes. We hope to learn how to spot these changes earlier in Black Americans.

We are enrolling Black Americans who are age 65+, concerned about their memory, and interested in a 10-week research study from the comfort of their own homes that includes: 

 

Answering health-related questions using paper, a telephone, and a mobile device 

Using several devices at home, including a wristwatch, thermometer, and blood pressure monitor 

Providing a blood sample 

 

Learn more

Please contact us at (206) 277-1379 for more information.

The lead researcher of this study is Dr. Debby Tsuang at S182 GRECC, VA Puget Sound, 1660 S. Columbian Way, Seattle WA 98108.

For More Information